Skip to main content
. 2021 Feb 16;12:1047. doi: 10.1038/s41467-021-21383-1

Fig. 4. Survival analysis of patients after neoadjuvant anti-OX40 administration.

Fig. 4

Patients were followed for disease-free (DFS) and overall survival (OS). a Kaplan–Meier estimate of DFS (orange) and OS (blue). The numbers below the graph represent the number of patients at risk. N = 17 head and neck squamous cell carcinoma (HNSCC) patients. Supplementary Table 4b contains the survival estimate for the overall and disease-free survival dataset as outlined in Gebski et al.31. b DFS in immune-responding (N = 4, blue) vs non-responding (N = 13, orange) HNSCC patients. The log-rank test (Mantel–Cox) was used to compare both curves and P values < 0.05 were considered statistically significant. Source data are provided as Source Data file.